See more : TD SYNNEX Corporation (SNX) Income Statement Analysis – Financial Results
Complete financial analysis of Third Harmonic Bio, Inc. (THRD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Third Harmonic Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- RBC Bearings Incorporated (RBC) Income Statement Analysis – Financial Results
- Invesco Perpetual Select Trust plc – Managed Liquidity Share Portfolio (IVPM.L) Income Statement Analysis – Financial Results
- Seowon Co., Ltd. (021050.KS) Income Statement Analysis – Financial Results
- SiS Distribution (Thailand) Public Company Limited (SIS.BK) Income Statement Analysis – Financial Results
- Sumuka Agro Industries Limited (SUMUKA.BO) Income Statement Analysis – Financial Results
Third Harmonic Bio, Inc. (THRD)
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 35.00K | 38.00K | 0.00 | 0.00 |
| Gross Profit | -35.00K | -38.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.96M | 24.41M | 15.75M | 9.95M |
| General & Administrative | 19.99M | 13.30M | 3.26M | 1.17M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.99M | 13.30M | 3.26M | 1.17M |
| Other Expenses | 0.00 | 2.55M | -10.61M | -1.69M |
| Operating Expenses | 43.92M | 37.71M | 19.00M | 11.12M |
| Cost & Expenses | 43.95M | 37.71M | 19.00M | 11.12M |
| Interest Income | 13.13M | 2.55K | 5.00 | 0.00 |
| Interest Expense | 0.00 | 2.55M | 0.00 | 0.00 |
| Depreciation & Amortization | 35.00K | 38.00K | 19.00M | 11.12M |
| EBITDA | -30.79M | -35.12M | -10.61M | -1.69M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -43.95M | -37.71M | -19.00M | -11.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 13.13M | 2.55M | -10.61M | -1.69M |
| Income Before Tax | -30.82M | -35.16M | -29.61M | -12.81M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.55M | -19.00K | -1.00K |
| Net Income | -30.82M | -37.71M | -29.61M | -12.81M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.78 | -0.96 | -0.77 | -0.33 |
| EPS Diluted | -0.78 | -0.96 | -0.77 | -0.33 |
| Weighted Avg Shares Out | 39.65M | 39.38M | 38.69M | 38.69M |
| Weighted Avg Shares Out (Dil) | 39.65M | 39.38M | 38.69M | 38.69M |
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference
SAN FRANCISCO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chris Murphy, Chief Financial...
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Third Harmonic Bio, Inc. (THRD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in November
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that management will participate in...
Third Harmonic Bio Announces Third Quarter 2024 Financial Results
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio,...
Third Harmonic Bio to Participate in Upcoming Investor Conferences in September
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie...
Third Harmonic Bio to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer Natalie...
Third Harmonic Bio Announces Second Quarter 2024 Financial Results and Provides Business Update
THB335 Phase 1 SAD/MAD clinical trial progressing; study now on track to report clinical results in 1Q'25 Strong financial position with cash and cash equivalents totaling $255.3 million as of June 30, 2024 SAN FRANCISCO, Aug. 08, 2024 (GLOBE NEWSWIRE) --...
Third Harmonic Bio to Participate in the Jefferies Global Healthcare Conference
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal, respiratory, and gastrointestinal inflammatory diseases, today announced that Chief Executive Officer, Natalie...
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
U.S. FDA clears Investigational New Drug application for THB335 Phase 1 SAD/MAD clinical trial initiated and subject screening underway, with results expected during 1H'25 Strengthened leadership team with the appointment of Christopher J. Dinsmore, Ph.D.
Third Harmonic Bio Appoints Geoff McDonough, M.D., to its Board of Directors
SAN FRANCISCO, March 28, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical company focused on advancing the next wave of medicine for inflammatory diseases, today announced the appointment of Geoff McDonough, M.D., to its Board of...
Source: https://incomestatements.info
Category: Stock Reports